Efficacy and Safety of Neoadjuvant Nivolumab Plus SOX Versus Nivolumab Plus FLOT in Patients With HER2-negative Gastric and Gastroesophageal Junction Adenocarcinoma

NCT06440811 · clinicaltrials.gov ↗

COMPLETED

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Immune-related Adverse Event
Chemotherapeutic Toxicity
Gastric or Gastroesophageal Junction Adenocarcinoma

Sponsor

Xijing Hospital